These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Fox KAA, Gibson CM. Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287 [Abstract] [Full Text] [Related]
25. Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention. Pareek M, Bhatt DL, Ten Berg JM, Kristensen SD, Grove EL. Expert Opin Pharmacother; 2017 Jun; 18(9):875-883. PubMed ID: 28489475 [Abstract] [Full Text] [Related]
31. Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits? Asencio LA, Huang JJ, Alpert JS. Am J Med; 2014 Jul; 127(7):579-85. PubMed ID: 24608021 [Abstract] [Full Text] [Related]
32. Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. Gao F, Zhou YJ, Wang ZJ, Yang SW, Nie B, Liu XL, Jia de A, Yan ZX. Int J Cardiol; 2011 Apr 01; 148(1):96-101. PubMed ID: 21185095 [Abstract] [Full Text] [Related]
34. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, van Eickels M, Lip GY, Cohen M, Husted S, Peterson E, Fox K. Am Heart J; 2015 Apr 01; 169(4):472-8.e5. PubMed ID: 25819853 [Abstract] [Full Text] [Related]
35. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Lip GY, Clementy N, Pericart L, Banerjee A, Fauchier L. Stroke; 2015 Jan 01; 46(1):143-50. PubMed ID: 25424474 [Abstract] [Full Text] [Related]
36. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. Kerneis M, Gibson CM, Chi G, Mehran R, AlKhalfan F, Talib U, Pahlavani S, Mir M, Bode C, Halperin JL, Nafee T, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Fox KAA, Cohen M. JACC Cardiovasc Interv; 2018 Apr 09; 11(7):626-634. PubMed ID: 29550085 [Abstract] [Full Text] [Related]
39. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Bahit MC, Lopes RD, Wojdyla DM, Hohnloser SH, Alexander JH, Lewis BS, Aylward PE, Verheugt FW, Keltai M, Diaz R, Hanna M, Granger CB, Wallentin L. Int J Cardiol; 2013 Dec 10; 170(2):215-20. PubMed ID: 24192334 [Abstract] [Full Text] [Related]